Therefore, some initial studies restricted to aggressive and poorly-differentiated colorectal and pancreatic carcinomas observed negligible amounts of CDH17 and presumed that CDH17 was generally reduced in advanced colorectal and pancreatic cancer. Here, CDH17 is linked to exocrine pancreatic carcinoma.